Sonoma Pharmaceuticals Expands HOCl Technology Reach with Major US Retail and Hospital Launches
核心洞察
Sonoma Pharmaceuticals launched its hypochlorous acid-based diaper rash (搜索) product in 3,600 Walmart stores and Amazon (搜索), marking the company's first major US consumer retail expansion.
The company partnered with Medline Industries (搜索) to launch a new HOCl wound cleanser for US hospitals, combining Sonoma's stabilized hypochlorous acid technology with Medline's extensive healthcare distribution network.
These launches represent significant milestones in Sonoma's US market expansion strategy, bringing clinically proven HOCl products to both consumer and professional healthcare settings.
Sonoma Pharmaceuticals has achieved two major commercial milestones in expanding access to its stabilized hypochlorous acid (HOCl) technology across US markets, launching both a consumer diaper rash (搜索) product in major retail chains and a professional wound cleanser for hospital systems.
Consumer Market Breakthrough
The Boulder, Colorado-based company announced in August 2025 that its HOCl-based diaper rash (搜索) product for infants and children is now available in 3,600 Walmart stores, Amazon (搜索).com, and select large grocery chains. The antimicrobial hydrogel is being marketed and sold through Sonoma's US-based distribution partner, representing the company's first major consumer-focused product launch in the United States.
"We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "We are also pleased about the increased availability of our Microcyn (搜索) technology for consumers who seek safe and effective solutions for diaper rash (搜索) and other skin irritations."
Hospital System Partnership
In October 2025, Sonoma announced a collaboration with Medline Industries (搜索) to launch a new HOCl wound cleanser manufactured by Sonoma for distribution into hospital systems, home healthcare, and other healthcare channels across the United States. The partnership, initiated in 2024, combines Sonoma's expertise in developing HOCl-based solutions with Medline's extensive hospital and healthcare distribution network.
The new product provides clinicians with an advanced wound cleansing solution designed to promote healing and reduce infection risk without damaging healthy tissue. Medline, headquartered in Northfield, Illinois, operates in over 100 countries and territories with more than 39,000 employees worldwide.
"We are very excited for the launch of the new HOCl wound cleanser into hospitals in the United States, which marks a significant milestone in the growth of our U.S. business," Trombly stated. "The substantial efforts by both Sonoma and Medline to make this possible reflect the value to patients and doctors in bringing our wound care technology to major hospital systems."
Technology Foundation
Both products are based on Sonoma's patented Microcyn (搜索) technology, which produces stabilized hypochlorous acid for various healthcare applications including wound care, eye care, oral and nasal care, dermatological conditions, podiatry, and animal health care. According to the company, its products are clinically proven to reduce itch, pain, scarring, and irritation safely without damaging healthy tissue.
In-vitro and clinical studies of HOCl demonstrate its ability to safely manage skin abrasions (搜索), lacerations (搜索), minor irritations, cuts, and intact skin. The technology has established a global presence, with Sonoma's products sold either directly or via partners in 55 countries worldwide.
Market Expansion Strategy
These launches represent a significant expansion of Sonoma's US market presence. The company operates with its principal office in Boulder, Colorado, manufacturing operations in Guadalajara, Mexico, and European marketing and sales headquarters in Roermond, Netherlands. The dual approach of targeting both consumer retail and professional healthcare markets demonstrates the versatility and broad applicability of the company's HOCl technology platform.